You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Suppliers and packagers for generic pharmaceutical drug: bupropion hydrochloride


✉ Email this page to a colleague

« Back to Dashboard


bupropion hydrochloride

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Accord Hlthcare BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 210497 ANDA Accord Healthcare Inc. 16729-443-10 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-443-10) 2018-11-08
Accord Hlthcare BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 210497 ANDA Accord Healthcare Inc. 16729-443-15 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-443-15) 2018-11-08
Accord Hlthcare BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 210497 ANDA Accord Healthcare Inc. 16729-443-16 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-443-16) 2018-11-08
Accord Hlthcare BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 210497 ANDA Accord Healthcare Inc. 16729-444-10 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-444-10) 2019-03-25
Accord Hlthcare BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 210497 ANDA Accord Healthcare Inc. 16729-444-16 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-444-16) 2019-03-25
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for Bupropion Hydrochloride

Last updated: February 19, 2026

Multiple pharmaceutical companies manufacture bupropion hydrochloride, a widely prescribed antidepressant and smoking cessation aid. The following outlines key suppliers, manufacturing guidelines, and market dynamics.

Major Manufacturers and Suppliers

Global and Regional Players

  • Teva Pharmaceuticals: One of the largest generic drug producers globally. Holds multiple patents and manufacturing rights for bupropion hydrochloride.
  • Mylan (now part of Viatris): Supplies branded and generic formulations, including immediate-release, sustained-release, and extended-release versions.
  • Sandoz (Novartis): Produces generic bupropion HCl, with active pharmaceutical ingredient (API) supply.
  • Aurobindo Pharma: Manufactures both API and finished dosages, with a global distribution network.
  • Lupin Pharmaceuticals: Key supplier for multiple regions, especially in Asia and Europe.
  • Sun Pharmaceutical Industries: Active in the API market, with production capacities in the United States and India.

API Suppliers

  • Akral Pharma: Supplies bulk API, with manufacturing facilities aligned with Good Manufacturing Practice (GMP).
  • Hetero Labs: Provides API for generic formulations, with supply agreements in North America, Europe, and Asia.
  • Cipla: Supplies API and finished formulations to various markets.

Supply Chain and Market Dynamics

  • API Market: Dominated by India and China, accounting for over 70% of global API production capacity (2019–2022). Many suppliers in these countries have established long-term contracts with pharmaceutical firms.
  • Regulatory Requirements: Suppliers must adhere to GMP standards issued by agencies such as the US FDA, EMA, and WHO. This limits the pool of qualified API manufacturers.

Regulatory Considerations

  • FDA Approval: US suppliers with approved Abbreviated New Drug Applications (ANDAs) are preferred in the US market.
  • EMA Certification: European suppliers require compliance with EU GMP standards.
  • Quality Assurance: Suppliers often undergo audits and inspections by regulatory agencies or third-party auditors.

Market Trends

  • Increased demand for generic formulations due to patent expirations.
  • Supply chain shifts towards regional API manufacturing to mitigate geopolitical and pandemic-related disruptions.
  • Expansion of manufacturing capacity in India and China for cost competitiveness.

Key Suppliers Summary Table

Supplier Primary Products Regions Covered Regulatory Certification Capacity Status
Teva Bupropion Immediate/Extended-release Global (North America, Europe, Asia) FDA, EMA, WHO GMP High, established
Mylan (Viatris) Bupropion IR/ER North America, Europe FDA, EMA Large, global distribution
Sandoz Generic bupropion HCl US, Europe, Asia FDA, EMA Moderate, scalable
Aurobindo Pharma API and finished formulations India, US, Europe GMP, FDA Expanding
Lupin API and formulations Asia, US, Europe WHO GMP, US FDA High

Conclusion

Bupropion HCl is supplied by a mix of large multinational generics firms and regional API manufacturers. Leading suppliers maintain regulatory compliance and significant manufacturing capacities, with India and China representing the primary source regions for API production.


Key Takeaways

  • Major global suppliers include Teva, Viatris (Mylan), Sandoz, Aurobindo, Lupin, and Sun Pharma.
  • API production is concentrated in India and China, with high regulatory standards governing quality.
  • Supply chain resilience relies on establishing GMP compliance and capacity expansion.
  • The market is influenced heavily by patent expirations and regional regulatory policies.

FAQs

  1. What are the primary regions supplying API for bupropion hydrochloride?

    • India and China dominate API production, accounting for over 70% of global capacity.
  2. Which regulatory standards must suppliers meet for US markets?

    • Good Manufacturing Practice (GMP) and approval via the FDA's Abbreviated New Drug Application (ANDA).
  3. Are there regional differences in bupropion hydrochloride suppliers?

    • Yes, while global firms supply the US and EU, regional suppliers in India and China primarily supply Asia and emerging markets.
  4. How has patent expiration affected supplier competition?

    • Patent expirations have increased generic market entries, boosting competition among suppliers.
  5. What are the main factors influencing supplier selection for pharmaceutical companies?

    • Regulatory compliance, manufacturing capacity, quality consistency, and supply chain reliability.

References

  1. U.S. Food and Drug Administration. (2022). Inactive Ingredient Database. https://www.fda.gov/cosmetics/cosmetic-products/ingredients-used-cosmetic-products
  2. MarketWatch. (2023). Global API market to reach USD 552.4 billion by 2027. https://www.marketwatch.com
  3. Indian Pharmacopoeia Commission. (2021). API manufacturing standards. https://www.ipc.gov.in/
  4. European Medicines Agency. (2022). Good Manufacturing Practice. https://www.ema.europa.eu
  5. WIPO. (2020). Patent statistics for pharmaceuticals. https://www.wipo.int

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.